drugset / Trial / NCT00006482

Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix

NCT00006482 ↗

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and cisplatin in treating patients who have refractory or recurrent cancer of the cervix.

Timeline

Start
2000-10
Primary completion
2006-04
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 30 mg/m2 Intravenous
Subject Gemcitabine Small molecule 800 mg/m2 Intravenous

Indications